These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

899 related items for PubMed ID: 18995992

  • 21. In vitro activity of tigecycline against 2423 clinical isolates and comparison of the available interpretation breakpoints.
    Papaparaskevas J, Tzouvelekis LS, Tsakris A, Pittaras TE, Legakis NJ, Hellenic Tigecycline Study Group.
    Diagn Microbiol Infect Dis; 2010 Feb; 66(2):187-94. PubMed ID: 19836184
    [Abstract] [Full Text] [Related]

  • 22. Susceptibility to tigecycline of isolates from samples collected in hospitalized patients with secondary peritonitis undergoing surgery.
    Tubau F, Liñares J, Rodríguez MD, Cercenado E, Aldea MJ, González-Romo F, Torroba L, Berdonces P, Plazas J, Aguilar L, Delgado A, García-Escribano N, Study Group.
    Diagn Microbiol Infect Dis; 2010 Mar; 66(3):308-13. PubMed ID: 20022193
    [Abstract] [Full Text] [Related]

  • 23. Antimicrobial susceptibility among gram-positive and gram-negative blood-borne pathogens collected between 2012-2016 as part of the Tigecycline Evaluation and Surveillance Trial.
    Zhang Z, Chen M, Yu Y, Pan S, Liu Y.
    Antimicrob Resist Infect Control; 2018 Mar; 7():152. PubMed ID: 30564308
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Antimicrobial susceptibility trends among gram-positive and -negative clinical isolates collected between 2005 and 2012 in Mexico: results from the Tigecycline Evaluation and Surveillance Trial.
    Morfin-Otero R, Noriega ER, Dowzicky MJ.
    Ann Clin Microbiol Antimicrob; 2015 Dec 15; 14():53. PubMed ID: 26667651
    [Abstract] [Full Text] [Related]

  • 26. Trending 7 years of in vitro activity of tigecycline and comparators against Gram-positive and Gram-negative pathogens from the Asia-Pacific region: Tigecycline Evaluation Surveillance Trial (TEST) 2004-2010.
    Hawser SP, Bouchillon SK, Hackel M, Chen M, Kim EC.
    Int J Antimicrob Agents; 2012 Jun 15; 39(6):490-5. PubMed ID: 22534507
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Global in vitro activity of tigecycline and linezolid against Gram-positive organisms collected between 2004 and 2009.
    Dowzicky MJ, Chmelařová E.
    Int J Antimicrob Agents; 2011 Jun 15; 37(6):562-6. PubMed ID: 21497066
    [Abstract] [Full Text] [Related]

  • 30. Antimicrobial susceptibility of Gram-positive bacterial isolates from the Asia-Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: a SENTRY Program Report (2003-2004).
    Biedenbach DJ, Bell JM, Sader HS, Fritsche TR, Jones RN, Turnidge JD.
    Int J Antimicrob Agents; 2007 Aug 15; 30(2):143-9. PubMed ID: 17531446
    [Abstract] [Full Text] [Related]

  • 31. Distribution of resistant gram-positive organisms across the census regions of the United States and in vitro activity of tigecycline, a new glycylcycline antimicrobial.
    Denys GA, Koch KM, Dowzicky MJ.
    Am J Infect Control; 2007 Oct 15; 35(8):521-6. PubMed ID: 17936143
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. In vitro activity of tigecycline and comparators against Gram-negative pathogens isolated from blood in Europe (2004-2009).
    Andrasevic AT, Dowzicky MJ.
    Int J Antimicrob Agents; 2012 Feb 15; 39(2):115-23. PubMed ID: 22189391
    [Abstract] [Full Text] [Related]

  • 35. Tigecycline: a novel glycylcycline antibiotic.
    Zhanel GG, Karlowsky JA, Rubinstein E, Hoban DJ.
    Expert Rev Anti Infect Ther; 2006 Feb 15; 4(1):9-25. PubMed ID: 16441206
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Regional variations in multidrug resistance among Enterobacteriaceae in the USA and comparative activity of tigecycline, a new glycylcycline antimicrobial.
    DiPersio JR, Dowzicky MJ.
    Int J Antimicrob Agents; 2007 May 15; 29(5):518-27. PubMed ID: 17376657
    [Abstract] [Full Text] [Related]

  • 38. In vitro activity of tigecycline (GAR-936) tested against 11,859 recent clinical isolates associated with community-acquired respiratory tract and gram-positive cutaneous infections.
    Fritsche TR, Kirby JT, Jones RN.
    Diagn Microbiol Infect Dis; 2004 Jul 15; 49(3):201-9. PubMed ID: 15246511
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Tigecycline: an investigational glycylcycline antimicrobial with activity against resistant gram-positive organisms.
    Garrison MW, Neumiller JJ, Setter SM.
    Clin Ther; 2005 Jan 15; 27(1):12-22. PubMed ID: 15763603
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 45.